搜尋
NewAmsterdam Pharma Company NV
NAMS添加自選
27.790USD
-0.670-2.35%
收盤 07-31 16:00（美東）報價延遲15分鐘
3.25B總市值
虧損本益比TTM
關於 NewAmsterdam Pharma Company NV 公司
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
NewAmsterdam Pharma Company NV簡介
公司代碼NAMS
公司名稱NewAmsterdam Pharma Company NV
上市日期Nov 23, 2022
CEODavidson (Michael Harvey)
員工數量68
證券類型Ordinary Share
年結日Nov 23
公司地址Gooimeer 2-35
城市NAARDEN
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Netherlands
郵編1411 DC
電話31352062971
網址https://ir.newamsterdampharma.com/
公司代碼NAMS
上市日期Nov 23, 2022
CEODavidson (Michael Harvey)
NewAmsterdam Pharma Company NV公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. John W. Smither
Mr. John W. Smither
Temporary Non-Executive Independent Director
Temporary Non-Executive Independent Director
2.32K
--
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
2.32K
--
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Dr. John Kastelein
Dr. John Kastelein
Chief Scientific Officer, Non-Executive Director
Chief Scientific Officer, Non-Executive Director
--
--
Ms. Juliette Audet
Ms. Juliette Audet
Chief Business Officer
Chief Business Officer
--
--
Dr. Louis Lange, M.D., Ph.D.
Dr. Louis Lange, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Nicholas Downing, M.D.
Dr. Nicholas Downing, M.D.
Director
Director
--
--
Ms. Janneke Van Der Kamp
Ms. Janneke Van Der Kamp
Temporary Non-Executive Director
Temporary Non-Executive Director
--
--
Dr. Marc Ditmarsch, M.D.
Dr. Marc Ditmarsch, M.D.
Chief Development Officer
Chief Development Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. John W. Smither
Mr. John W. Smither
Temporary Non-Executive Independent Director
Temporary Non-Executive Independent Director
2.32K
--
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
2.32K
--
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Dr. John Kastelein
Dr. John Kastelein
Chief Scientific Officer, Non-Executive Director
Chief Scientific Officer, Non-Executive Director
--
--
Ms. Juliette Audet
Ms. Juliette Audet
Chief Business Officer
Chief Business Officer
--
--
常見問題
NewAmsterdam Pharma Company NV的前五大股東是誰？
NewAmsterdam Pharma Company NV的前五大股東如下：Mr. John W. Smither
有多少機構持有NewAmsterdam Pharma Company NV(NAMS)的股份？
截至2026Q1，共有366家機構持有NewAmsterdam Pharma Company NV的股份，合計持有的股份價值約為128.70M，占公司總股份的110.09% 。與2025Q4相比，機構持股有所增加，增幅為2432976.00。